A Single-arm Clinical Study of Autologous Tumor-Infiltrating Lymphocyte (GT201 Injection ) for Treatment of Patients with Advanced Lung Cancer
This study is a single arm, open design aimed at evaluating the safety and tolerability of Autologous Tumor-Infiltrating Lymphocyte (GT201 injection ) for treatment of patients with Advanced lung cancer,while evaluating pharmacokinetic characteristics and efficacy assessment.
• 1\. Voluntarily join the study, signed informed consent form，willing and able to comply with the study protocol;
• 2\. Age 18 to 70 years old;
• 3\. Queue 1: Late stage non-small cell lung cancer without driver genes that have failed first-line systemic treatment;Queue 2: Small cell lung cancer with first-line systemic treatment failure;
• 4\. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;
• 5\. Expected survival time of ≥ 12 weeks;
• 6\. Good function of vital organs;
• 7\. Subjects entering this study due to disease progression must have an imaging record of disease progression before tumor sampling;
• 8\. At least one measurable target lesion that meets the definition of RECIST v1.1 after tumor sampling.